title: [Efficacy of Avastin in combination with irinotecan for metastatic colorectal cancer].
abstract: OBJECTIVE
  To evaluate the efficacy of Avastin in combination with irinotecan for metastatic colorectal cancer.
  
  
  METHODS
  Ninety patients were randomly divided into 3 equal groups to receive Avastin plus irinotecan (group A), FOLFIRI (group B) and FOLFOX7 (group C) for two cycles, respectively. The response rate and changes in tumor maker levels were observed.
  
  
  RESULTS
  The tumor response rate was 43.3% in group A, 27.7% in group B and 30.0% in group C. The disease control rate (complete response+partial response+stable disease) was 80% in group A, 53.3% in group B and 50.0% in group C. Obvious changes in tumor marker levels were observed in the 3 groups after treatment, which were most conspicuous in group A (P<0.05).
  
  
  CONCLUSIONS
  The addition of Avastin to irinotecan chemotherapy results in significant improvement of clinical efficacy in patients with metastatic colorectal cancer.
authors.affiliation: Center of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. zhengh@fimmu.com
authors.forename: Hang
authors.initials: H
authors.lastname: Zheng
authors.forename: Jin-zhang
authors.initials: JZ
authors.lastname: Chen
authors.forename: Wang-jun
authors.initials: WJ
authors.lastname: Liao
authors.forename: Rong-cheng
authors.initials: RC
authors.lastname: Luo
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D000077146:Irinotecan; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D000077146:Irinotecan; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin